Sphingosine 1-phosphate signaling at the blood-brain barrier

Trends in Molecular Medicine

Volumn 21, Issue 6, 2015, Pages 354-363

  Prager, Briana ^a   Spampinato, Simona F ^b,c   Ransohoff, Richard M ^a,b,d  

^a CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CATANIA   (Italy)

^d BIOGEN   (United States)

Author keywords

Astrocyte; Blood brain barrier; Fingolimod; Multiple sclerosis; Neuroinflammation; Sphingosine 1 phosphate

Indexed keywords

FINGOLIMOD; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; IMMUNOLOGIC FACTOR; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ASTROCYTE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; ENDOTHELIUM CELL; HUMAN; MEMBRANE PERMEABILITY; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; CAPILLARY PERMEABILITY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; ASTROCYTES; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; ENDOTHELIAL CELLS; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOLOGIC FACTORS; LYSOPHOSPHOLIPIDS; MULTIPLE SCLEROSIS; RECEPTORS, LYSOSPHINGOLIPID; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84930541286     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.03.006     Document Type: Review

References (119)

1. Ransohoff R.M., Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 2012, 12:623-635.
2. Obermeier B., et al. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 2013, 19:1584-1596.
3. Coomber B.L., Stewart P.A. Three-dimensional reconstruction of vesicles in endothelium of blood-brain barrier versus highly permeable microvessels. Anat. Rec. 1986, 215:256-261.
4. Taddei A., et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5. Nat. Cell Biol. 2008, 10:923-934.
5. Alvarez J.I., et al. Glial influence on the blood brain barrier. Glia 2013, 61:1939-1958.
6. Luissint A-C., et al. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 2012, 9:23.
7. Winkler E.A., et al. Central nervous system pericytes in health and disease. Nat. Neurosci. 2011, 14:1398-1405.
8. Abbott N.J., et al. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
9. Prat A., et al. Glial cell influence on the human blood-brain barrier. Glia 2001, 36:145-155.
10. Rubin L.L. The blood-brain barrier in and out of cell culture. Curr. Opin. Neurobiol. 1991, 1:360-363.
11. Pfaff D., et al. Emerging roles of the angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking. J. Leukoc. Biol. 2006, 80:719-726.
12. Suri C., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
13. Murakami M., et al. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 2008, 118:3355-3366.
14. Reuss B., et al. Functions of fibroblast growth factor (FGF)-2 and FGF-5 in astroglial differentiation and blood-brain barrier permeability: evidence from mouse mutants. J. Neurosci. 2003, 23:6404-6412.
15. Igarashi Y., et al. Glial cell line-derived neurotrophic factor induces barrier function of endothelial cells forming the blood-brain barrier. Biochem. Biophys. Res. Commun. 1999, 261:108-112.
16. Jaillard C., et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 2005, 25:1459-1469.
17. Kimura A., et al. Antagonism of sphingosine 1-phosphate receptor-2 enhances migration of neural progenitor cells toward an area of brain. Stroke 2008, 39:3411-3417.
18. Noda H., et al. Fingolimod phosphate promotes the neuroprotective effects of microglia. J. Neuroimmunol. 2013, 256:13-18.
19. Wu C., et al. Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation. J. Neuroinflamm. 2013, 10:41.
20. Garcia J.G., et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J. Clin. Invest. 2001, 108:689-701.
21. Galea I., et al. What is immune privilege (not)?. Trends Immunol. 2007, 28:12-18.
22. Engelhardt B., Ransohoff R.M. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol. 2012, 33:579-589.
23. Lyck R., Engelhardt B. Going against the tide - how encephalitogenic T cells breach the blood-brain barrier. J. Vasc. Res. 2012, 49:497-509.
24. De Vries H.E., et al. Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease. Epilepsia 2012, 53:45-52.
25. Gimsa U., et al. Immune privilege as an intrinsic CNS property: astrocytes protect the CNS against T-cell-mediated neuroinflammation. Mediat. Inflamm. 2013, 2013:1-11.
26. Glushakova O., et al. Delayed increases in microvascular pathology following experimental traumatic brain injury are associated with prolonged inflammation, blood brain barrier disruption and progressive white matter damage. J. Neurotrauma 2014, 31:1180-1193.
27. Winkler E.A., et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:E1035-E1042.
28. Gao F., et al. Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Pharmacol. Biochem. Behav. 2012, 103:187-196.
29. Jin A.Y., et al. Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic stroke: a future therapeutic target for treatment of stroke. BMC Neurosci. 2010, 11:12.
30. Lu L., et al. Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage. Brain Res. 2014, 1555:89-96.
31. Dubois L.G., et al. Gliomas and the vascular fragility of the blood brain barrier. Front. Cell. Neurosci. 2014, 8:418.
32. Murata N., et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 2000, 352:809-815.
33. Chun J., et al. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 2002, 54:265-269.
34. Kluk M.J., Hla T. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim. Biophys. Acta 2002, 1582:72-80.
35. Kipp M., Amor S. FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination. Mult. Scler. 2012, 18:258-263.
36. 1 receptor. Trends Pharmacol. Sci. 2013, 34:401-412.
37. Siehler S., Manning D.R. Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors. Biochim. Biophys. Acta 2002, 1582:94-99.
38. Blaho V.A., Hla T. An update on the biology of sphingosine 1-phosphate receptors. J. Lipid Res. 2014, 55:1596-1608.
39. Kumar A., Saba J.D. Lyase to live by: sphingosine phosphate lyase as a therapeutic target. Expert Opin. Ther. Targets 2009, 13:1013-1025.
40. Brinkmann V., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 2010, 9:883-897.
41. Cohen J.A., Chun J. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 2011, 69:759-777.
42. Daum G., et al. Sphingosine 1-phosphate: a regulator of arterial lesions. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1439-1443.
43. Koch A., et al. Sphingosine 1-phosphate in renal diseases. Cell. Physiol. Biochem. 2013, 31:745-760.
44. Abbasi T., Garcia J.G.N. Sphingolipids in lung endothelial biology and regulation of vascular integrity. Sphingolipids in Disease 2013, 201-226. Springer. E. Gulbins, I. Petrache (Eds.).
45. Miron V.E., et al. Central nervous system-directed effects of FTY720 (fingolimod). J. Neurol. Sci. 2008, 274:13-17.
46. Takasugi N., et al. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate. J. Neurosci. 2011, 31:6850-6857.
47. Halmer R., et al. Sphingolipids: important players in multiple sclerosis. Cell. Physiol. Biochem. 2014, 34:111-118.
48. Fukuhara S., et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J. Clin. Invest. 2012, 122:1416-1426.
49. Garris C.S., et al. Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond. Immunology 2014, 142:347-353.
50. Brinkmann V., et al. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 2004, 4:1019-1025.
51. Lewis N.D., et al. Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3. J. Immunol. 2013, 190:3533-3540.
52. Cruz-Orengo L., et al. Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility. J. Clin. Invest. 2014, 124:2571-2584.
53. 3 function coordinately during embryonic angiogenesis. J. Biol. Chem. 2004, 279:29367-29373.
54. 1 acts within endothelial cells to regulate vascular maturation. Blood 2003, 102:3665-3667.
55. Takuwa Y. Roles of sphingosine-1-phosphate signaling in angiogenesis. World J. Biol. Chem. 2010, 1:298.
56. Liu Y., et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest. 2000, 106:951-961.
57. Gaengel K., et al. The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev. Cell 2012, 23:587-599.
58. Bazzoni G., Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol. Rev. 2004, 84:869-901.
59. Wójciak-Stothard B., et al. Rho and Rac but not Cdc42 regulate endothelial cell permeability. J. Cell Sci. 2001, 114:1343-1355.
60. Lee M.J., et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell 1999, 99:301-312.
61. 3. J. Clin. Invest. 2004, 113:569-581.
62. Salomone S., et al. Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br. J. Pharmacol. 2008, 153:140-147.
63. Minagar A., et al. Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult. Scler. 2003, 9:235-238.
64. Sanchez T., et al. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler. Thromb. Vasc. Biol. 2007, 27:1312-1318.
65. Shen W., et al. Tyrosine phosphorylation of VE-cadherin and claudin-5 is associated with TGF-β1-induced permeability of centrally derived vascular endothelium. Eur. J. Cell Biol. 2011, 90:323-332.
66. Zhang W., et al. Sphingosine-1-phosphate receptor-2 mediated NFκB activation contributes to tumor necrosis factor-α induced VCAM-1 and ICAM-1 expression in endothelial cells. Prostaglandins Other Lipid Mediat. 2013, 106:62-71.
67. Akahoshi N., et al. Frequent spontaneous seizures followed by spatial working memory/anxiety deficits in mice lacking sphingosine 1-phosphate receptor 2. Epilepsy Behav. 2011, 22:659-665.
68. Du J., et al. LPS and TNF-α induce expression of sphingosine-1-phosphate receptor-2 in human microvascular endothelial cells. Pathol. Res. Pract. 2012, 208:82-88.
69. Bigaud M., et al. Second generation S1P pathway modulators: research strategies and clinical developments. Biochim. Biophys. Acta 2014, 1841:745-758.
70. 5 expression in MS grey and white matter lesions. Neuropathol. Appl. Neurobiol. 2014, 40:564-578.
71. Furukawa A., et al. Production of nerve growth factor enhanced in cultured mouse astrocytes by glycerophospholipids, sphingolipids, and their related compounds. Mol. Cell. Biochem. 2007, 305:27-34.
72. Pébay A., et al. Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur. J. Neurosci. 2001, 13:2067-2076.
73. Sato K., et al. Sphingosine 1-phosphate induces expression of early growth response-1 and fibroblast growth factor-2 through mechanism involving extracellular signal-regulated kinase in astroglial cells. Brain Res. Mol. Brain Res. 1999, 74:182-189.
74. Rouach N., et al. S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur. J. Neurosci. 2006, 23:1453-1464.
75. Van Doorn R., et al. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. Acta Neuropathol. 2012, 124:397-410.
76. Fischer I., et al. Sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 are functionally upregulated on astrocytes under pro-inflammatory conditions. PLoS ONE 2011, 6:e23905.
77. 1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 2007, 25:115-124.
78. Lee D.H., et al. Altered expression of sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 in mouse hippocampus after kainic acid treatment. Biochem. Biophys. Res. Commun. 2010, 393:476-480.
79. 1) modulation. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:751-756.
80. Colombo E., et al. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann. Neurol. 2014, 76:325-337.
81. Adachi K., Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect. Med. Chem. 2008, 1:11-23.
82. Adachi K., et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg. Med. Chem. Lett. 1995, 5:853-856.
83. Cohen J.A., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:402-415.
84. Kappos L., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
85. 1 receptors. Nat. Chem. Biol. 2009, 5:428-434.
86. Gräler M.H., Goetzl E.J. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 2004, 18:551-553.
87. Bandhuvula P., et al. The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J. Biol. Chem. 2005, 280:33697-33700.
88. Chun J., Hartung H-P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 2010, 33:91-101.
89. 1 receptor agonists - part 3: from thiophenes to pyridines. J. Med. Chem. 2014, 57:110-130.
90. Brunkhorst R., et al. FTY720 treatment in the convalescence period improves functional recovery and reduces reactive astrogliosis in photothrombotic stroke. PLoS ONE 2013, 8:e70124.
91. Di Menna L., et al. Fingolimod protects cultured cortical neurons against excitotoxic death. Pharmacol. Res. 2013, 67:1-9.
92. Foster C.A., et al. FTY720 rescue therapy in the Dark Agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage. Brain Pathol. 2009, 19:254-266.
93. Van Doorn R., et al. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions. Glia 2010, 58:1465-1476.
94. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 2002, 200:629-638.
95. Argaw A.T., et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J. Clin. Invest. 2012, 122:2454-2468.
96. 1) phosphorylation exacerbates Th17-mediated autoimmune neuroinflammation. Nat. Immunol. 2013, 14:1166-1172.
97. De Vries H.E., et al. The influence of cytokines on the integrity of the blood-brain barrier in vitro. J. Neuroimmunol. 1996, 64:37-43.
98. Garcia C.M., et al. Endothelial cell-astrocyte interactions and TGF beta are required for induction of blood-neural barrier properties. Brain Res. Dev. Brain Res. 2004, 152:25-38.
99. Walshe T.E., et al. TGF-β is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS ONE 2009, 4:e5149.
100. Xin C., et al. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses. J. Biol. Chem. 2004, 279:35255-35262.
101. Cannon R.E., et al. Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:15930-15935.
102. Van Doorn R., et al. Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier. J. Neuroinflamm. 2012, 9:133.
103. Sanchez T. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 2003, 278:47281-47290.
104. Stadelmann C. Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications. Curr. Opin. Neurol. 2011, 24:224-229.
105. Cartwright T.A., et al. Mrp1 is essential for sphingolipid signaling to p-glycoprotein in mouse blood-brain and blood-spinal cord barriers. J. Cereb. Blood Flow Metab. 2013, 33:381-388.
106. Morales I., et al. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front. Cell. Neurosci. 2014, 8:112.
107. Miron V.E., et al. Cyclical and dose-dependent responses of adult human mature oligodendrocytes to fingolimod. Am. J. Pathol. 2008, 173:1143-1152.
108. Rivers T.M., et al. Observations on attempts to produce acute disseminated encephalomyelitis in monkeys. J. Exp. Med. 1933, 58:39-53.
109. Ben-Nun A., et al. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J. Autoimmun. 2014, 54:33-50.
110. Terry R.L., et al. Experimental autoimmune encephalomyelitis in mice. Methods Mol. Biol. 2014, Published online July 9, 2014. 10.1007/7651_2014_88.
111. Robinson A.P., et al. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb. Clin. Neurol. 2014, 122:173-189.
112. O'Connor R.A., et al. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 2008, 181:3750-3754.
113. Johnson K.P., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 2001, 57:S16-S24.
114. Teitelbaum D., et al. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1971, 1:242-248.
115. Teitelbaum D., et al. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J. Neuroimmunol. 1996, 64:209-217.
116. Yednock T.A., et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
117. Webb M., et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 2004, 153:108-121.
118. Fujino M., et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 2003, 305:70-77.
119. Ransohoff R.M. Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 2012, 15:1074-1077.